| UCB S.A. UNSP.ADR 1/2 |
| USA |
| Gesundheit |
| US9034801012 / A14WZY |
| UNC0 (Frankfurt) |
| FRA:UNC0, ETR:UNC0, UNC0:GR |
| - |
| https://www.ucb.com/ |
|
UCB S.A. is an innovative global biopharmaceutical company based in Belgium, known for its focus on developing therapies for severe diseases in immunology and neurology. UCB aims to provide high-impact solutions for conditions affecting millions worl..
>Volltext.. |
| 50857.84 Mio. EUR |
| 50628.92 Mio. EUR |
| 7597.31 Mio. EUR |
| 2596.98 Mio. EUR |
| 1543.63 Mio. EUR |
| 4.06 EUR |
| 2284.16 Mio. EUR |
| 2290.26 Mio. EUR |
| 2185.37 Mio. EUR |
| 0.56 |
| 31.78% |
| 54.6% |
| 0.68 EUR |
| 0.33% |
| 0.33% |
| 28.04.25 - 0.6781829€ 26.04.24 - 0.6246308€ >weitere anzeigen... |
| - |
| UCB ADR, UCB |
| 05.04.26 |
|